약물 약동 및 독성 평가를 위한 장/간 미생물학 시스템

Executive Industry Relevance

This microphysiological system enables human-relevant pharmacokinetic and toxicological assessment by integrating intestinal and liver organoids, addressing a key gap in preclinical drug evaluation. By emulating oral and intravenous dosing routes and measuring APAP absorption and metabolism, the system supports mechanistic de-risking and improves predictive confidence in early discovery. The platform offers translational continuity from in vitro screening to preclinical modeling, reducing reliance on animal data and enhancing portfolio triage decisions.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of first-pass metabolism and gut-liver axis interactions for target validation.
• Operational Value: Provides human tissue-based models to de-risk mechanistic assumptions about drug absorption and metabolism.
• Predictive Value: Supports hypothesis testing on drug disposition pathways to improve target confidence and portfolio triage.

Screening & Assay Development

• Scientific Value: Generates quantitative PK and toxicity readouts via HPLC and HCA for assay standardization.
• Operational Value: Delivers reproducible, flow-dependent liver functionality and stable intestinal barrier metrics (TEER, viability).
• Scalability Value: Supports medium-throughput screening with integrated sampling and multiparametric organoid analysis.

Translational & Preclinical Research

• Scientific Value: Bridges discovery and preclinical stages by emulating human APAP PK and toxicological responses.
• Operational Value: Enables cross-functional alignment through shared, quantifiable datasets (media HPLC, organoid gene/protein expression).
• Risk Mitigation: Improves prediction of human DILI and absorption variability, supporting go/no-go decisions.

Pipeline & Workflow Integration

The system fits within the discovery continuum, supporting early ADME-tox profiling after target identification and before lead optimization, with outputs informing medicinal chemistry and DMPK teams.

• Discovery Biology: Facilitates mechanistic de-risking of absorption and metabolism hypotheses using human-relevant tissue models.
• Screening: Delivers assay-ready, standardized organoid cultures with quantifiable apical-to-basolateral transport and metabolic clearance.
• Analytics: Provides HPLC-derived PK profiles and HCA-based early toxicity signals for comparative condition analysis.
• Translational Research: Connects in vitro findings to preclinical expectations via human-like gut-liver interplay and metabolite formation.
• Enterprise Reuse: Establishes a reusable platform for multiple compounds, reducing redevelopment effort across projects.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence in human PK/tox, reduction of mechanistic ambiguity in gut-liver axis modeling.
• Operational Value: Standardized microfluidic perfusion, reproducible TEER and viability metrics, scalable sampling.
• Strategic Value: Earlier, more accurate go/no-go decisions, reduced late-stage attrition from PK/tox surprises.
• Portfolio Impact: Risk-adjusted compound prioritization based on human-relevant absorption and metabolism data.

Implementation Considerations

• Expertise in organoid culture, microfluidic operation, and HPLC-based PK analysis.
• Instrumentation for TEER measurement, fluorescence microscopy, and plate-based viability assays (MTT, HCA).
• Cross-team standardization of sampling timing, media composition, and organoid quality criteria.
• Adaptation considerations for other compound classes beyond APAP, particularly those with efflux or uptake transporter dependence.
• Practical limitations include donor variability in organoid function and the need for careful flow calibration to avoid shear stress.

Biopharma FAQs